← Back to Clinical Trials
Recruiting NCT04833335

ASL in Brain Metastasis MRI Following Gamma Knife Treatment

Trial Parameters

Condition Brain Metastases
Sponsor Assistance Publique - Hôpitaux de Paris
Study Type INTERVENTIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-01-24
Completion 2028-09-24
Interventions
MRI perfusion sequence

Brief Summary

Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The primary target of the study is to establish the diagnostic performances (specificity, sensitivity) of quantitative measures of ASL in brain metastases suspected of progression/radionecrosis after GK treatment

Eligibility Criteria

Inclusion Criteria: * Brain metastasis from histologically proven tumor * GK treatment within 4 month prior to the inclusion * Lesions suspected of progression/ radionecrosis : i.e.≥ 25% of the size progression * Lesion size: gadolinium enhanced part of the tumour ≥1 cm Exclusion Criteria: * Pregnancy * Medical history of primitive brain tumour * MRI incompatibility/ medical history of contrast agent allergy * Claustrophobia * Patient unable to consent * Epilepsia/recent stroke * Patients participating in other studies * Patients without health care insurance

Related Trials